Selection of Appropriate Non-clinical Animal Models to Ensure Translatability of Novel AAV-gene Therapies to the Clinic

Overview

Journal Gene Ther

Date 2023 Aug 23

PMID 37612361

Authors

Mark Singh

Andrew Brooks

Parto Toofan

Keith McLuckie

Affiliations

Soon will be listed here.

Abstract

Gene Therapy Medicinal Products consist of a recombinant nucleic acid intended for the modulation or manipulation of a genetic sequence. A single administration of a novel gene therapy has the potential to be curative, with a durable long-term benefit to patients. Adeno-associated viral vectors have become the viral vector of choice for in vivo delivery of therapeutic transgenes as they are mildly immunogenic, can effectively transduce a variety of human tissues and cells, and have low levels of genomic integration. Central to the effective translation of data generated in discovery studies to the clinic is the selection of appropriate animal species for pivotal non-clinical studies. This review aims to support the selection of appropriate animal models for non-clinical studies to advance the development of novel adeno-associated virus gene therapies.

Citing Articles

Systemic delivery of AAV5, AAV8, and AAV9 packaging a C5-12-microdystrophin-FLAG expression cassette in non-human primates.

Liu M, Cook E, Dai Y, Ehlert E, du Plessis F, Lubelski J Mol Ther Methods Clin Dev. 2025; 33(1):101411.

PMID: 40027261 PMC: 11869850. DOI: 10.1016/j.omtm.2025.101411.

Gene therapy for CNS disorders: modalities, delivery and translational challenges.

Gao J, Gunasekar S, Xia Z, Shalin K, Jiang C, Chen H Nat Rev Neurosci. 2024; 25(8):553-572.

PMID: 38898231 DOI: 10.1038/s41583-024-00829-7.

References

Prakash V, Moore M, Yanez-Munoz R . Current Progress in Therapeutic Gene Editing for Monogenic Diseases. Mol Ther. 2016; 24(3):465-74. PMC: 4786935. DOI: 10.1038/mt.2016.5. View

McColgan P, Tabrizi S . Huntington's disease: a clinical review. Eur J Neurol. 2017; 25(1):24-34. DOI: 10.1111/ene.13413. View

Tabrizi S, Flower M, Ross C, Wild E . Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat Rev Neurol. 2020; 16(10):529-546. DOI: 10.1038/s41582-020-0389-4. View

Oura S, Noda T, Morimura N, Hitoshi S, Nishimasu H, Nagai Y . Precise CAG repeat contraction in a Huntington's Disease mouse model is enabled by gene editing with SpCas9-NG. Commun Biol. 2021; 4(1):771. PMC: 8222283. DOI: 10.1038/s42003-021-02304-w. View

Das S, Menezes M, Bhatia S, Wang X, Emdad L, Sarkar D . Gene Therapies for Cancer: Strategies, Challenges and Successes. J Cell Physiol. 2014; 230(2):259-71. PMC: 4363073. DOI: 10.1002/jcp.24791. View

Sterner R, Sterner R . CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021; 11(4):69. PMC: 8024391. DOI: 10.1038/s41408-021-00459-7. View

Balakrishnan B, Jayandharan G . Basic biology of adeno-associated virus (AAV) vectors used in gene therapy. Curr Gene Ther. 2014; 14(2):86-100. DOI: 10.2174/1566523214666140302193709. View

Wu Z, Asokan A, Samulski R . Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther. 2006; 14(3):316-27. DOI: 10.1016/j.ymthe.2006.05.009. View

Gao G, Vandenberghe L, Alvira M, Lu Y, Calcedo R, Zhou X . Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol. 2004; 78(12):6381-8. PMC: 416542. DOI: 10.1128/JVI.78.12.6381-6388.2004. View

10.

Agbandje-Mckenna M, Kleinschmidt J . AAV capsid structure and cell interactions. Methods Mol Biol. 2011; 807:47-92. DOI: 10.1007/978-1-61779-370-7_3. View

11.

Weinmann J, Grimm D . Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes. 2017; 53(5):707-713. DOI: 10.1007/s11262-017-1502-7. View

12.

Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus M . Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010; 21(6):704-12. DOI: 10.1089/hum.2009.182. View

13.

Grimm D, Zolotukhin S . E Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal--Tailored Acceleration of AAV Evolution. Mol Ther. 2015; 23(12):1819-31. PMC: 4700111. DOI: 10.1038/mt.2015.173. View

14.

A Kotterman M, Schaffer D . Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet. 2014; 15(7):445-51. PMC: 4393649. DOI: 10.1038/nrg3742. View

15.

Bartel M, Schaffer D, Buning H . Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity. Front Microbiol. 2011; 2:204. PMC: 3207363. DOI: 10.3389/fmicb.2011.00204. View

16.

Bartel M, Weinstein J, Schaffer D . Directed evolution of novel adeno-associated viruses for therapeutic gene delivery. Gene Ther. 2012; 19(6):694-700. DOI: 10.1038/gt.2012.20. View

17.

Hacker U, Bentler M, Kaniowska D, Morgan M, Buning H . Towards Clinical Implementation of Adeno-Associated Virus (AAV) Vectors for Cancer Gene Therapy: Current Status and Future Perspectives. Cancers (Basel). 2020; 12(7). PMC: 7409174. DOI: 10.3390/cancers12071889. View

18.

Erles K, Rohde V, Thaele M, Roth S, Edler L, Schlehofer J . DNA of adeno-associated virus (AAV) in testicular tissue and in abnormal semen samples. Hum Reprod. 2001; 16(11):2333-7. DOI: 10.1093/humrep/16.11.2333. View

19.

He X, Urip B, Zhang Z, Ngan C, Feng B . Evolving AAV-delivered therapeutics towards ultimate cures. J Mol Med (Berl). 2021; 99(5):593-617. PMC: 7885987. DOI: 10.1007/s00109-020-02034-2. View

20.

Arruda V, Fields P, Milner R, Wainwright L, De Miguel M, Donovan P . Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. Mol Ther. 2001; 4(6):586-92. DOI: 10.1006/mthe.2001.0491. View